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In the early 1960s Hoffman La-Roche, a Swiss pharmaceutical
company, introduced Librium (chlordiazepoxide) and Valium
(diazepam) for the treatment of anxiety. Members of a new class
of drugs named benzodiazepines, they were immediate best-
sellers. In The Age of Anxiety Andrea Tone (2008), a Professor
of the Social History of Medicine at McGill, describes the people,
the companies, and the cultural forces that brought us these
medications and considers their societal impact. In telling these
stories Tone also helps us anticipate the reaction to the new
drugs for anxiety that are on the way.
Benzodiazepines were not the first antianxiety drugs to enjoy
an enthusiastic reception. Tone starts the book by describing
Wallace Laboratories’ discovery of their immediate predecessor,
meprobamate (Miltown), which was introduced in 1955 and re-
vealed the unexpected demand for what the public called chill
pills. Eager for a share of this huge new market, other drug
companies rushed to compete. Some tried to make patentable
knock-offs of meprobamate, a me-too approach that remains
popular, but they didn’t get very far. Roche decided to take
a much riskier approach by asking their chemists to hunt for
something truly novel by trial and error.
The leading advocate of the trial and error approach was Leo
Sternbach, a chemist whom Roche had rescued from the Nazis
andwho had established himself as a gifted innovator. Having no
idea what kind of chemicals might reduce anxiety, Sternbach
decided to make a series of derivatives of a synthetic dye that
he had studied in the past and submitted them for behavioral
testing in mice. Amazingly, one of them worked: mice treated
with the new compound were much easier to handle, a sign of
decreased anxiety, yet were not as sedated as those who took
meprobamate. The same was true in more sophisticated behav-
ioral tests in animals and in anxious patients. Furthermore this
drug, which became Librium, had very little toxicity. Tone
describes how its usefulness was then quickly established in
clinical trials that were far less stringent than those that are
required today, and how its superiority to Miltown was subse-
quently confirmed.
Having discovered the value of this new compound, Stern-
bach continued his tinkering. He soon made Valium, which
wasmuchmore potent than Librium and became an even bigger
blockbuster. Over the years other popular benzodiazepines such
as Klonopin (clonazepam) flowed from his lab and their clinical
values were established by the rigorous criteria that the FDA
had by then put in place.
Benzodiazepines were not only helpful for patients. They also
turned out to be valuable tools for basic neurobiological research.
The first breakthrough came in 1975 with the discovery that
benzodiazepinesworkbyaugmenting theactionsofGABA,which
made them useful for studying inhibitory neurotransmission.
Subsequent studies showed that these actions are somewhat
selective because they only bind to regulatory sites on certain
forms of theGABA-A receptor, and this opened upmany produc-
tive lines of investigation.
While these exciting discoveries were being made, the dark
side of benzodiazepines was also becoming apparent, as Tone
describes in considerable detail. One of their troublesome
features is that the dose required to relieve anxiety also produces
some sedation and slowing of cognition. They also have a much
bigger drawback: all of them are potentially habit forming.
Although most people can be taught to use these valuable drugs
without getting into trouble, some become physically and
psychologically dependent on them and may even become
addicted.
Despite these drawbacks sales boomed. Fueled by a vigorous
advertising and marketing campaign that was an early example
of those that are now all too familiar, physicians began
prescribing Valium for any sign of emotional distress and it
became the number one prescription drug for a decade. Stay-
at-home moms were Valium’s major consumers, but men also
began to rely on it to help them deal with the pressures of their
jobs. For some it proved very helpful. For those who were simply
swept up by this latest fad it did more harm than good.
Eventually there was public criticism of the overuse of these
medications. Tone’s most memorable example is the Rolling
Stones’ hit song,Mother’s Little Helper, which lamented a house-
wife’s dependence on her little yellow pill. Public advocacy
groups also joined in the attack and condemned what they
considered to be overzealous promotion of drugs to people
who don’t really need them. Their case was greatly strengthened
by stories of the abuse of benzodiazepines by public figures
such as President Gerald Ford’s wife, Betty Ford.
All this negative publicity took its toll. Tone explains how the
outcry led to the FDA’s classification of benzodiazepines as
controlled substances, which constrained their marketing andNeuron 62, May 28, 2009 ª2009 Elsevier Inc. 461
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despite this constraint, benzodiazepines are still the most widely
prescribed drugs for anxiety even though dependence and other
side effects remain a problem.
But there is more to the story of these medications that Tone
does not cover—because it is going on behind the closed labo-
ratory doors of several major drug companies. Recognizing the
drawbacks of the existing medications, scientists at these
companies continue to look for ways to improve them, and
much of this work is based on a growing understanding of
GABA-A receptors (Barondes, 2003). We now know that these
receptors are made by combining various alpha, beta, and
gamma subunits to give complex structures including four
subtypes—alpha 1-, 2-, 3-, and 5-containing—that have benzo-
diazepine-binding sites. Furthermore, pharmacological experi-
ments have shown that binding to different subtypes has
different behavioral effects: selective agonists for the benzodiaz-
epine-binding site of the alpha 1 subtype cause sleepiness,
those for alpha 2 and 3 reduce anxiety, and those for alpha 5
impair cognition and memory.
Many of these selective agonists are not members of the
benzodiazepine family. A notable example is Ambien (zolpidem),
a nonbenzodiazepine that is selective for alpha 1 and has
become an extremely popular sleeping pill. But the most tanta-
lizing goal of this research program is a pill that reduces anxiety
without causing sleepiness or cognitive impairment and that is
also—a big also—not addictive. This is the challenge that several
companies have accepted.
So far Merck has published most extensively about subtype-
selective GABA-A modulators such as L-838,417 and TPA-023
(also known as MK-0777) (Atack, 2008). L-838,417 is a partial
agonist at alpha 2, 3, and 5 and an antagonist at alpha 1, and it
reduces anxiety with few sedative and cognitive effects. TPA-
023, which has one less fluorine and one more methyl, looks
even more promising. It too is a partial agonist at alpha 2 and 3
but not at alpha 5, raising the possibility that it would have
even fewer undesirable side effects. Furthermore, the fact that
these compounds are only partial rather than full agonists at
alpha 2 and 3 raises the hope that they may not be addictive.462 Neuron 62, May 28, 2009 ª2009 Elsevier Inc.But there are many potholes on the road to drug development,
and Merck’s compounds aren’t yet on the way to approval as
treatments for anxiety. Roche’s scientists are also exploring
this area but are keeping their findings close to their chests. To
the best of my knowledge, only AstraZeneca has a GABA-A
receptor subtype partial agonist (AZD7325) in clinical trials for
anxiety disorders, although details about its properties have
not been made public. Drugs that influence other potential
targets in anxiety-generating brain circuits are also being evalu-
ated by a number of companies.
Should nonsedating and nonaddicting medications make it to
the clinic, they will be extremely valuable for patients with
disabling anxiety. Yet they, too, will not be trouble-free. As
Tone and others (Elliott, 2003; President’s Council on Bioethics,
2003) remind us, all medications that affect the mind are
frequently prescribed for people who don’t need them and can
also be diverted for illegal misuse. It’s not hard to imagine the
misuse of any drug that can reduce anxiety below the level
required for effective psychological functioning: chilling out
may be wonderful, but only up to a point.
Nevertheless it seems likely that the personal and societal
downside of such new pharmaceuticals will be considerably
less than that of their predecessors. It is a prediction that I
hope we will see tested in the not-too-distant future.
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